Our technology converts fat-soluble and insoluble ingredients into highly potent, water-soluble forms with high active payloads (10%+), proven shelf stability, and no harsh chemicals, making it easier to add ingredients like vitamins A, D, E, and K to formats where they would otherwise be difficult to use
Declines with age (50% reduction by age 60)
What the research shows, and what maintenance really looks like In large randomized trials, semaglutide produced roughly 15 percent average body weight loss over 68 weeks and tirzepatide produced roughly 20 to 22 percent
Browse the peptide education library References European Medicines Agency
Cagrilintide at a glance What it is Cagrilintide (AM833), a long-acting synthetic amylin analog / amylin-receptor agonist Researched for Weight management and metabolic disease in obesity/overweight and type 2 diabetes research contexts Commonly reported range 0.25 mg to 4.5 mg once weekly in trials